Bishop Emma J, Howden Benjamin P
Austin Health, Infectious Diseases Department, Studley Road, Heidelberg, 3084, Victoria, Australia.
Expert Opin Emerg Drugs. 2007 Mar;12(1):1-22. doi: 10.1517/14728214.12.1.1.
Infections due to Staphylococcus aureus are a major cause of morbidity and mortality worldwide. Antimicrobial resistance in strains of S. aureus is a continually evolving problem, including widespread methicillin resistance in hospitals, increasing methicillin resistance in community strains, and the recent acquisition of glycopeptide resistance. New antimicrobials with activity against S. aureus have recently entered the market or are in the late stages of development. In addition, there has been significant interest in the development of novel and immune-based strategies for prevention or treatment of S. aureus infections. This review describes established and emerging therapies for S. aureus infections, and considers the safety profiles and likely impact on present treatment standards of novel agents either undergoing clinical development or emerging onto the market.
金黄色葡萄球菌感染是全球发病和死亡的主要原因。金黄色葡萄球菌菌株中的抗菌药物耐药性是一个不断演变的问题，包括医院中广泛存在的耐甲氧西林情况、社区菌株中耐甲氧西林情况的增加以及最近出现的糖肽类耐药性。具有抗金黄色葡萄球菌活性的新型抗菌药物最近已进入市场或正处于开发后期。此外，人们对开发预防或治疗金黄色葡萄球菌感染的新型免疫疗法也有浓厚兴趣。本综述描述了已确立的和新出现的金黄色葡萄球菌感染治疗方法，并考虑了正在进行临床开发或即将上市的新型药物的安全性概况及其对当前治疗标准可能产生的影响。
